Cellular Composition and 5hmC Signature Predict the Treatment Response of AML Patients to Azacitidine Combined with Chemotherapy
Azacitidine (AZA) is a DNA methyltransferase inhibitor and epigenetic modulator that can be an effective agent in combination with chemotherapy for patients with high-risk acute myeloid leukemia (AML). However, biological factors driving the therapeutic response of such hypomethylating agent (HMA)-based therapies remain unknown. Herein, the transcriptome and/or genome-wide 5-hydroxymethylcytosine (5hmC) are characterized for 41 patients with high-risk AML from a phase 1 clinical trial treated with AZA epigenetic priming followed by high-dose cytarabine and mitoxantrone (AZA-HiDAC-Mito). Digital cytometry reveals that responders have elevated Granulocyte-macrophage-progenitor-like (GMP-like) malignant cells displaying an active cell cycle program. Moreover, the enrichment of Natural killer (NK) cells predicts favorable outcome in patients receiving AZA-HiDAC-Mito therapy or other AZA-based therapies. Comparing 5hmC profiles before and after five-day treatment of AZA shows that AZA exposure induces dose-dependent 5hmC changes, the magnitude of which predicts overall survival (p=0.015). An XGBoost machine learning model is developed to predict the treatment response based on 5hmC levels of only 11 genes, achieving an area under the curve (AUC) of 0.860. These results suggest that cellular composition markedly impacts the treatment response, and showcase the prospect of 5hmC signature in predicting the outcomes of HMA-based therapies in AML. Overall design: A total of 46 patients who received AZA-HiDAC-Mito therapy (AZA epigenetic priming followed by high-dose cytarabine and mitoxantrone) were enrolled in this study, out of which 41 provided usable RNA and/or 5hmC sequencing data. Samples were collected at Day 0 (before treatment) and Day 5 (after 5 days of AZA treatment) from BM and PB. There were 71 samples from 31 patients for RNA-seq and 120 samples from 40 patients for 5hmC-seq. For patients receiving HiDAC-Mito therapy, there were 22 RNA-seq samples and 23 DNA 5hmC samples from 23 AML patients collected before treatment. For patients only receiving AZA treatment, there were 11 RNA-seq samples and 12 5hmC-seq samples collected before treatment.